Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Anticonvulsants × Clear all

Phase

Phase NA 1 Phase 4 1 Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis Complex-associated Refractory Seizures 1

Interventions

Cisplatin 634 Carboplatin 527 Paclitaxel 508 Cyclophosphamide 468 Radiotherapy 463 Docetaxel 423 Fluorouracil 402 Gemcitabine 378 Doxorubicin 357 Capecitabine 325 Dexamethasone 289 Oxaliplatin 259 Vincristine 248 Leucovorin 248 Etoposide 245 pembrolizumab 240 Bevacizumab 237 Rituximab 221 Prednisone 207 Pemetrexed 187 Cytarabine 185 Drug Therapy 176 Methotrexate 155 Trastuzumab 154 Irinotecan 149 Lenalidomide 126 Filgrastim 122 Nivolumab 117 Tamoxifen 113 Chemotherapy, Adjuvant 113

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01713946 2018-11-07

EXIST-3

Novartis

Phase 3 Completed

366 enrolled 38 charts 1 FDA

Tuberous Sclerosis Complex-associated Refractory Seizures

Data powered by HemOnc (CC BY 4.0) Colophon ⚡